NCT05288582已完成不适用
Tear Lipid Layer Thickness Assessments With Perfluorohexyloctane Eye Drops
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Tear lipid layer thickness
研究概览
简要总结
The purpose of this study is to explore the tear lipid layer quantitatively and qualitatively before and after use of a perflurohexyloctane eye drop (NovaTears)
详细描述
The tear lipid layer will be studied before and after the use of an over-the-counter eye drop (NovaTears, Novaliq GmbH, Heidelberg, Germany) using a Stroboscopic Video Color Microscope, which is non-invasive.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •• Age - at least 30 years
- •Good general health (defined by medication use that has not changed within the last month and the absence of medical conditions or treatments that are deemed confounding to the data as determined by the PI)
- •Ability to give informed consent
- •Willing to spend time for the study; approximately one hour for a screening visit and 45 minutes for a data collection visit.
- •Either gender
- •Any racial or ethnic origin
- •tear lipid thickness ≤ 75 nm
排除标准
- •Active ocular inflammation
- •Use of any ocular prescription medication (such as but not limited to, glaucoma medications, anti-inflammatory eye drops and Restasis or Xiidra) used within 14 days of the screening visit or started prior to the measurement visit(s).
- •Currently having punctal plugs inserted in lacrimal puncta
- •Current eye disease, infection or inflammation that affects the surface of the eye such as, but not limited to moderate or greater blepharitis and ocular allergy. Clinically significant (active treatment) of blepharitis, Sjogren's disease or other systemic disease that could influence MGD, corneal, conjunctival, or eyelid abnormalities that could influence lipid layer thickness, conjunctivitis of any cause, ocular infection or systemic medication such as diuretics, SSRIs, that could influence tear secretion, or sensitivity to any of the ingredient in the eye drop being tested,
- •Past eye surgery, such as, but not limited to, refractive surgery. Subjects who have had cataract removal surgery more than one year ago may be considered as potential subjects.
- •Female subjects may not be pregnant or lactating. (Subject will be asked to self-report these conditions.)
- •Infectious diseases (for example, hepatitis, tuberculosis) or an immuno-suppressive disease (for example, HIV). (Subjects will be asked to self-report these conditions.)
- •Inability to complete the screening and examination
- •Inability to provide analyzable data. For example, subjects who cannot keep their eye open during the entire measurement interval (due to early blinking) or provide a readable eye image (due to eyelid laxity) or cannot sit still for 1 minute.
研究组 & 干预措施
Perfluorohexyloctane eye drop
Other
Participants will have their tear lipid layer assessed. They will then have the eye drop instilled and will have an additional assessment of the tear lipid layer within 5 minutes of instillation of the the drop, and again 15 minutes after instillation.
干预措施: NovaTears (Device)
结局指标
主要结局
Tear lipid layer thickness
时间窗: 15 minutes
次要结局
未报告次要终点
研究者
Jennifer Fogt
PI
Ohio State University
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Changes of Tear-film Lipid Layer Thickness and Ocular Aberration After Treatment of Meibomian Gland DysfunctionMeibomian Gland DysfunctionNCT02618304Yonsei University45
已完成
不适用
Evaluation of Tear Film Lipid Layer Thickness Change After Cataract SurgeryCataract PatientsNCT02567565Yonsei University60
已完成
不适用
Tear Layer Lipid Thickness in Pterygium Patient Before and After SurgeryDry EyeNCT02160769Singapore National Eye Centre76
已完成
不适用
Formula Identification (FID) 114657 in Contact Lens WearersRefractive ErrorNCT02293538Alcon Research234
已完成
不适用
Diagnostic Evaluation of the Tear FilmDry Eye SyndromesNCT00761917TearScience, Inc.229